Trial Profile
Pharmacokinetics, Glucodynamics, Safety, and Tolerability of LY900014 in Patients With Type 2 Diabetes Mellitus on Multiple Daily Insulin Injection Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Insulin lispro (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 15 Sep 2017 Results of first-part of this study presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 13 Jun 2017 Results of first part, presented at the 77th Annual Scientific Sessions of the American Diabetes Association
- 26 Aug 2016 Status changed from active, no longer recruiting to completed.